-
1
-
-
79960299888
-
Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy
-
Rosenberg, S. A., J. C. Yang, R. M. Sherry, U. S. Kammula, M. S. Hughes, G. Q. Phan, D. E. Citrin, N. P. Restifo, P. F. Robbins, J. R. Wunderlich, et al. 2011. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin. Cancer Res. 17: 4550-4557. doi:10. 1158/1078-0432. CCR-11-0116.
-
(2011)
Clin. Cancer Res.
, vol.17
, pp. 4550-4557
-
-
Rosenberg, S.A.1
Yang, J.C.2
Sherry, R.M.3
Kammula, U.S.4
Hughes, M.S.5
Phan, G.Q.6
Citrin, D.E.7
Restifo, N.P.8
Robbins, P.F.9
Wunderlich, J.R.10
-
2
-
-
0023099992
-
Production of stable cytolytic T-cell clones directed against autologous human melanoma
-
Herin, M., C. Lemoine, P. Weynants, F. Vessiere, A. Van Pel, A. Knuth, R. Devos, and T. Boon. 1987. Production of stable cytolytic T-cell clones directed against autologous human melanoma. Int. J. Cancer 39: 390-396.
-
(1987)
Int. J. Cancer
, vol.39
, pp. 390-396
-
-
Herin, M.1
Lemoine, C.2
Weynants, P.3
Vessiere, F.4
Van Pel, A.5
Knuth, A.6
Devos, R.7
Boon, T.8
-
3
-
-
0023093741
-
Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma
-
Muul, L. M., P. J. Spiess, E. P. Director, and S. A. Rosenberg. 1987. Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma. J. Immunol. 138: 989-995.
-
(1987)
J. Immunol.
, vol.138
, pp. 989-995
-
-
Muul, L.M.1
Spiess, P.J.2
Director, E.P.3
Rosenberg, S.A.4
-
4
-
-
0344039007
-
Cytolytic T-cell clones against an autologous human melanoma: Specificity study and definition of three antigens by immunoselection
-
Knuth, A., T. Wölfel, E. Klehmann, T. Boon, and K. H. Meyer zum Buschenfelde. 1989. Cytolytic T-cell clones against an autologous human melanoma: specificity study and definition of three antigens by immunoselection. Proc. Natl. Acad. Sci. USA 86: 2804-2808.
-
(1989)
Proc. Natl. Acad. Sci. USA
, vol.86
, pp. 2804-2808
-
-
Knuth, A.1
Wölfel, T.2
Klehmann, E.3
Boon, T.4
Meyer Zum Buschenfelde, K.H.5
-
5
-
-
0026322151
-
A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma
-
van der Bruggen, P., C. Traversari, P. Chomez, C. Lurquin, E. De Plaen, B. Van den Eynde, A. Knuth, and T. Boon. 1991. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254: 1643-1647.
-
(1991)
Science
, vol.254
, pp. 1643-1647
-
-
Van Der Bruggen, P.1
Traversari, C.2
Chomez, P.3
Lurquin, C.4
De Plaen, E.5
Eynde Den B.Van6
Knuth, A.7
Boon, T.8
-
6
-
-
0028316911
-
Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor
-
Kawakami, Y., S. Eliyahu, C. H. Delgado, P. F. Robbins, L. Rivoltini, S. L. Topalian, T. Miki, and S. A. Rosenberg. 1994. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc. Natl. Acad. Sci. USA 91: 3515-3519.
-
(1994)
Proc. Natl. Acad. Sci. USA
, vol.91
, pp. 3515-3519
-
-
Kawakami, Y.1
Eliyahu, S.2
Delgado, C.H.3
Robbins, P.F.4
Rivoltini, L.5
Topalian, S.L.6
Miki, T.7
Rosenberg, S.A.8
-
7
-
-
33749624177
-
Cancer regression in patients after transfer of genetically engineered lymphocytes
-
Morgan, R. A., M. E. Dudley, J. R. Wunderlich, M. S. Hughes, J. C. Yang, R. M. Sherry, R. E. Royal, S. L. Topalian, U. S. Kammula, N. P. Restifo, et al. 2006. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314: 126-129.
-
(2006)
Science
, vol.314
, pp. 126-129
-
-
Morgan, R.A.1
Dudley, M.E.2
Wunderlich, J.R.3
Hughes, M.S.4
Yang, J.C.5
Sherry, R.M.6
Royal, R.E.7
Topalian, S.L.8
Kammula, U.S.9
Restifo, N.P.10
-
8
-
-
79952187823
-
T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis
-
Parkhurst, M. R., J. C. Yang, R. C. Langan, M. E. Dudley, D. A. Nathan, S. A. Feldman, J. L. Davis, R. A. Morgan, M. J. Merino, R. M. Sherry, et al. 2011. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol. Ther. 19: 620-626.
-
(2011)
Mol. Ther.
, vol.19
, pp. 620-626
-
-
Parkhurst, M.R.1
Yang, J.C.2
Langan, R.C.3
Dudley, M.E.4
Nathan, D.A.5
Feldman, S.A.6
Davis, J.L.7
Morgan, R.A.8
Merino, M.J.9
Sherry, R.M.10
-
9
-
-
0028304337
-
Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines
-
Cox, A. L., J. Skipper, Y. Chen, R. A. Henderson, T. L. Darrow, J. Shabanowitz, V. H. Engelhard, D. F. Hunt, and C. L. Slingluff, Jr. 1994. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 264: 716-719.
-
(1994)
Science
, vol.264
, pp. 716-719
-
-
Cox, A.L.1
Skipper, J.2
Chen, Y.3
Henderson, R.A.4
Darrow, T.L.5
Shabanowitz, J.6
Engelhard, V.H.7
Hunt, D.F.8
Slingluff, C.L.9
-
10
-
-
0033609729
-
Massspectrometric evaluation of HLA-A0201-associated peptides identifies dominant naturally processed forms of CTL epitopes from MART-1 and gp100
-
Skipper, J. C., P. H. Gulden, R. C. Hendrickson, N. Harthun, J. A. Caldwell, J. Shabanowitz, V. H. Engelhard, D. F. Hunt, and C. L. Slingluff, Jr. 1999. Massspectrometric evaluation of HLA-A0201-associated peptides identifies dominant naturally processed forms of CTL epitopes from MART-1 and gp100. Int. J. Cancer 82: 669-677.
-
(1999)
Int. J. Cancer
, vol.82
, pp. 669-677
-
-
Skipper, J.C.1
Gulden, P.H.2
Hendrickson, R.C.3
Harthun, N.4
Caldwell, J.A.5
Shabanowitz, J.6
Engelhard, V.H.7
Hunt, D.F.8
Slingluff, C.L.9
-
11
-
-
22244437207
-
Lessons to be learned from primary renal cell carcinomas: Novel tumor antigens and HLA ligands for immunotherapy
-
Kruger, T., O. Schoor, C. Lemmel, B. Kraemer, C. Reichle, J. Dengjel, T. Weinschenk, M. Muller, J. Hennenlotter, A. Stenzl, et al. 2005. Lessons to be learned from primary renal cell carcinomas: novel tumor antigens and HLA ligands for immunotherapy. Cancer Immunol. Immunother. 54: 826-836.
-
(2005)
Cancer Immunol. Immunother.
, vol.54
, pp. 826-836
-
-
Kruger, T.1
Schoor, O.2
Lemmel, C.3
Kraemer, B.4
Reichle, C.5
Dengjel, J.6
Weinschenk, T.7
Muller, M.8
Hennenlotter, J.9
Stenzl, A.10
-
12
-
-
13344282077
-
Human neoplasms elicit multiple specific immune responses in the autologous host
-
Sahin, U., O. Tureci, H. Schmitt, B. Cochlovius, T. Johannes, R. Schmits, F. Stenner, G. Luo, I. Schobert, and M. Pfreundschuh. 1995. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc. Natl. Acad. Sci. USA 92: 11810-11813.
-
(1995)
Proc. Natl. Acad. Sci. USA
, vol.92
, pp. 11810-11813
-
-
Sahin, U.1
Tureci, O.2
Schmitt, H.3
Cochlovius, B.4
Johannes, T.5
Schmits, R.6
Stenner, F.7
Luo, G.8
Schobert, I.9
Pfreundschuh, M.10
-
13
-
-
12644276375
-
A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening
-
Chen, Y. T., M. J. Scanlan, U. Sahin, O. Tureci, A. O. Gure, S. Tsang, B. Williamson, E. Stockert, M. Pfreundschuh, and L. J. Old. 1997. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc. Natl. Acad. Sci. USA 94: 1914-1918.
-
(1997)
Proc. Natl. Acad. Sci. USA
, vol.94
, pp. 1914-1918
-
-
Chen, Y.T.1
Scanlan, M.J.2
Sahin, U.3
Tureci, O.4
Gure, A.O.5
Tsang, S.6
Williamson, B.7
Stockert, E.8
Pfreundschuh, M.9
Old, L.J.10
-
14
-
-
0035888172
-
Monophasic and biphasic synovial sarcomas abundantly express cancer/testis antigen NY-ESO-1 but not MAGE-A1 or CT7
-
Jungbluth, A. A., C. R. Antonescu, K. J. Busam, K. Iversen, D. Kolb, K. Coplan, Y. T. Chen, E. Stockert, M. Ladanyi, and L. J. Old. 2001. Monophasic and biphasic synovial sarcomas abundantly express cancer/testis antigen NY-ESO-1 but not MAGE-A1 or CT7. Int. J. Cancer 94: 252-256.
-
(2001)
Int. J. Cancer
, vol.94
, pp. 252-256
-
-
Jungbluth, A.A.1
Antonescu, C.R.2
Busam, K.J.3
Iversen, K.4
Kolb, D.5
Coplan, K.6
Chen, Y.T.7
Stockert, E.8
Ladanyi, M.9
Old, L.J.10
-
15
-
-
32944457941
-
Tumor antigen expression in melanoma varies according to antigen and stage
-
Barrow, C., J. Browning, D. MacGregor, I. D. Davis, S. Sturrock, A. A. Jungbluth, and J. Cebon. 2006. Tumor antigen expression in melanoma varies according to antigen and stage. Clin. Cancer Res. 12: 764-771.
-
(2006)
Clin. Cancer Res.
, vol.12
, pp. 764-771
-
-
Barrow, C.1
Browning, J.2
MacGregor, D.3
Davis, I.D.4
Sturrock, S.5
Jungbluth, A.A.6
Cebon, J.7
-
16
-
-
28144457350
-
Cancertestis genes are coordinately expressed and are markers of poor outcome in nonsmall cell lung cancer
-
Gure, A. O., R. Chua, B. Williamson, M. Gonen, C. A. Ferrera, S. Gnjatic, G. Ritter, A. J. Simpson, Y. T. Chen, L. J. Old, and N. K. Altorki. 2005. Cancertestis genes are coordinately expressed and are markers of poor outcome in nonsmall cell lung cancer. Clin. Cancer Res. 11: 8055-8062.
-
(2005)
Clin. Cancer Res.
, vol.11
, pp. 8055-8062
-
-
Gure, A.O.1
Chua, R.2
Williamson, B.3
Gonen, M.4
Ferrera, C.A.5
Gnjatic, S.6
Ritter, G.7
Simpson, A.J.8
Chen, Y.T.9
Old, L.J.10
Altorki, N.K.11
-
17
-
-
84928912377
-
A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: Long-term follow-up and correlates with response
-
Robbins, P. F., S. H. Kassim, T. L. Tran, J. S. Crystal, R. A. Morgan, S. A. Feldman, J. C. Yang, M. E. Dudley, J. R. Wunderlich, R. M. Sherry, et al. 2015. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response. Clin. Cancer Res. 21: 1019-1027. doi:10. 1158/1078-0432. CCR-14-2708.
-
(2015)
Clin. Cancer Res.
, vol.21
, pp. 1019-1027
-
-
Robbins, P.F.1
Kassim, S.H.2
Tran, T.L.3
Crystal, J.S.4
Morgan, R.A.5
Feldman, S.A.6
Yang, J.C.7
Dudley, M.E.8
Wunderlich, J.R.9
Sherry, R.M.10
-
18
-
-
71049153709
-
Cancer/testis (CT) antigens: Potential targets for immunotherapy
-
Caballero, O. L., and Y. T. Chen. 2009. Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci. 100: 2014-2021.
-
(2009)
Cancer Sci.
, vol.100
, pp. 2014-2021
-
-
Caballero, O.L.1
Chen, Y.T.2
-
19
-
-
12844257369
-
MAGE-A3 is a frequent tumor antigen of metastasized melanoma
-
Roeder, C., B. Schuler-Thurner, S. Berchtold, G. Vieth, Pv. Driesch, G. Schuler, and M. Luftl. 2005. MAGE-A3 is a frequent tumor antigen of metastasized melanoma. Arch. Dermatol. Res. 296: 314-319.
-
(2005)
Arch. Dermatol. Res.
, vol.296
, pp. 314-319
-
-
Roeder, C.1
Schuler-Thurner, B.2
Berchtold, S.3
Vieth, G.4
Driesch, Pv.5
Schuler, G.6
Luftl, M.7
-
20
-
-
84863337890
-
B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells
-
Kochenderfer, J. N., M. E. Dudley, S. A. Feldman, W. H. Wilson, D. E. Spaner, I. Maric, M. Stetler-Stevenson, G. Q. Phan, M. S. Hughes, R. M. Sherry, et al. 2012. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 119: 2709-2720.
-
(2012)
Blood
, vol.119
, pp. 2709-2720
-
-
Kochenderfer, J.N.1
Dudley, M.E.2
Feldman, S.A.3
Wilson, W.H.4
Spaner, D.E.5
Maric, I.6
Stetler-Stevenson, M.7
Phan, G.Q.8
Hughes, M.S.9
Sherry, R.M.10
-
21
-
-
84876005284
-
CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia
-
Brentjens, R. J., M. L. Davila, I. Riviere, J. Park, X. Wang, L. G. Cowell, S. Bartido, J. Stefanski, C. Taylor, M. Olszewska, et al. 2013. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci. Transl. Med. 5: 177ra38.
-
(2013)
Sci. Transl. Med.
, vol.5
, pp. 177ra38
-
-
Brentjens, R.J.1
Davila, M.L.2
Riviere, I.3
Park, J.4
Wang, X.5
Cowell, L.G.6
Bartido, S.7
Stefanski, J.8
Taylor, C.9
Olszewska, M.10
-
22
-
-
84933510694
-
CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia
-
Maude, S. L., D. T. Teachey, D. L. Porter, and S. A. Grupp. 2015. CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Blood 125: 4017-4023.
-
(2015)
Blood
, vol.125
, pp. 4017-4023
-
-
Maude, S.L.1
Teachey, D.T.2
Porter, D.L.3
Grupp, S.A.4
-
23
-
-
33646440024
-
Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: First clinical experience
-
Lamers, C. H., S. Sleijfer, A. G. Vulto, W. H. Kruit, M. Kliffen, R. Debets, J. W. Gratama, G. Stoter, and E. Oosterwijk. 2006. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J. Clin. Oncol. 24: e20-e22.
-
(2006)
J. Clin. Oncol.
, vol.24
, pp. e20-e22
-
-
Lamers, C.H.1
Sleijfer, S.2
Vulto, A.G.3
Kruit, W.H.4
Kliffen, M.5
Debets, R.6
Gratama, J.W.7
Stoter, G.8
Oosterwijk, E.9
-
24
-
-
84878605813
-
Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: Clinical evaluation and management of on-target toxicity
-
Lamers, C. H., S. Sleijfer, S. van Steenbergen, P. van Elzakker, B. van Krimpen, C. Groot, A. Vulto, M. den Bakker, E. Oosterwijk, R. Debets, and J. W. Gratama. 2013. Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. Mol. Ther. 21: 904-912.
-
(2013)
Mol. Ther.
, vol.21
, pp. 904-912
-
-
Lamers, C.H.1
Sleijfer, S.2
Van Steenbergen, S.3
Van Elzakker, P.4
Van Krimpen, B.5
Groot, C.6
Vulto, A.7
Den Bakker, M.8
Oosterwijk, E.9
Debets, R.10
Gratama, J.W.11
-
25
-
-
77950475517
-
Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2
-
Morgan, R. A., J. C. Yang, M. Kitano, M. E. Dudley, C. M. Laurencot, and S. A. Rosenberg. 2010. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol. Ther. 18: 843-851.
-
(2010)
Mol. Ther.
, vol.18
, pp. 843-851
-
-
Morgan, R.A.1
Yang, J.C.2
Kitano, M.3
Dudley, M.E.4
Laurencot, C.M.5
Rosenberg, S.A.6
-
26
-
-
0029125899
-
A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma
-
Coulie, P. G., F. Lehmann, B. Lethé, J. Herman, C. Lurquin, M. Andrawiss, and T. Boon. 1995. A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc. Natl. Acad. Sci. USA 92: 7976-7980.
-
(1995)
Proc. Natl. Acad. Sci. USA
, vol.92
, pp. 7976-7980
-
-
Coulie, P.G.1
Lehmann, F.2
Lethé, B.3
Herman, J.4
Lurquin, C.5
Andrawiss, M.6
Boon, T.7
-
27
-
-
0028978274
-
A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma
-
Wölfel, T., M. Hauer, J. Schneider, M. Serrano, C. Wölfel, E. Klehmann-Hieb, E. De Plaen, T. Hankeln, K. H. Meyer zum Buschenfelde, and D. Beach. 1995. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 269: 1281-1284.
-
(1995)
Science
, vol.269
, pp. 1281-1284
-
-
Wölfel, T.1
Hauer, M.2
Schneider, J.3
Serrano, M.4
Wölfel, C.5
Klehmann-Hieb, E.6
De Plaen, E.7
Hankeln, T.8
Meyer Zum Buschenfelde, K.H.9
Beach, D.10
-
28
-
-
0029669950
-
A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes
-
Robbins, P. F., M. El-Gamil, Y. F. Li, Y. Kawakami, D. Loftus, E. Appella, and S. A. Rosenberg. 1996. A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J. Exp. Med. 183: 1185-1192.
-
(1996)
J. Exp. Med.
, vol.183
, pp. 1185-1192
-
-
Robbins, P.F.1
El-Gamil, M.2
Li, Y.F.3
Kawakami, Y.4
Loftus, D.5
Appella, E.6
Rosenberg, S.A.7
-
29
-
-
84920921528
-
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
-
Gubin, M. M., X. Zhang, H. Schuster, E. Caron, J. P. Ward, T. Noguchi, Y. Ivanova, J. Hundal, C. D. Arthur, W. J. Krebber, et al. 2014. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 515: 577-581.
-
(2014)
Nature
, vol.515
, pp. 577-581
-
-
Gubin, M.M.1
Zhang, X.2
Schuster, H.3
Caron, E.4
Ward, J.P.5
Noguchi, T.6
Ivanova, Y.7
Hundal, J.8
Arthur, C.D.9
Krebber, W.J.10
-
30
-
-
39549084433
-
NetMHCpan, a method for quantitative predictions of peptide binding to any HLA-A and-B locus protein of known sequence
-
Nielsen, M., C. Lundegaard, T. Blicher, K. Lamberth, M. Harndahl, S. Justesen, G. Røder, B. Peters, A. Sette, O. Lund, and S. Buus. 2007. NetMHCpan, a method for quantitative predictions of peptide binding to any HLA-A and-B locus protein of known sequence. PLoS One 2: e796.
-
(2007)
PLoS One
, vol.2
, pp. e796
-
-
Nielsen, M.1
Lundegaard, C.2
Blicher, T.3
Lamberth, K.4
Harndahl, M.5
Justesen, S.6
Røder, G.7
Peters, B.8
Sette, A.9
Lund, O.10
Buus, S.11
-
31
-
-
84880276438
-
Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells
-
Robbins, P. F., Y. C. Lu, M. El-Gamil, Y. F. Li, C. Gross, J. Gartner, J. C. Lin, J. K. Teer, P. Cliften, E. Tycksen, et al. 2013. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat. Med. 19: 747-752.
-
(2013)
Nat. Med.
, vol.19
, pp. 747-752
-
-
Robbins, P.F.1
Lu, Y.C.2
El-Gamil, M.3
Li, Y.F.4
Gross, C.5
Gartner, J.6
Lin, J.C.7
Teer, J.K.8
Cliften, P.9
Tycksen, E.10
-
32
-
-
84880507665
-
Mutational heterogeneity in cancer and the search for new cancer-associated genes
-
Lawrence, M. S., P. Stojanov, P. Polak, G. V. Kryukov, K. Cibulskis, A. Sivachenko, S. L. Carter, C. Stewart, C. H. Mermel, S. A. Roberts, et al. 2013. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499: 214-218.
-
(2013)
Nature
, vol.499
, pp. 214-218
-
-
Lawrence, M.S.1
Stojanov, P.2
Polak, P.3
Kryukov, G.V.4
Cibulskis, K.5
Sivachenko, A.6
Carter, S.L.7
Stewart, C.8
Mermel, C.H.9
Roberts, S.A.10
-
33
-
-
84872841412
-
Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma
-
van Rooij, N., M. M. van Buuren, D. Philips, A. Velds, M. Toebes, B. Heemskerk, L. J. van Dijk, S. Behjati, H. Hilkmann, D. El Atmioui, et al. 2013. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J. Clin. Oncol. 31: e439-e442.
-
(2013)
J. Clin. Oncol.
, vol.31
, pp. e439-e442
-
-
Van Rooij, N.1
Van Buuren, M.M.2
Philips, D.3
Velds, A.4
Toebes, M.5
Heemskerk, B.6
Van Dijk, L.J.7
Behjati, S.8
Hilkmann, H.9
El Atmioui, D.10
-
34
-
-
84918828514
-
Genetic basis for clinical response to CTLA-4 blockade in melanoma
-
Snyder, A., V. Makarov, T. Merghoub, J. Yuan, J. M. Zaretsky, A. Desrichard, L. A. Walsh, M. A. Postow, P. Wong, T. S. Ho, et al. 2014. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 371: 2189-2199.
-
(2014)
N. Engl. J. Med.
, vol.371
, pp. 2189-2199
-
-
Snyder, A.1
Makarov, V.2
Merghoub, T.3
Yuan, J.4
Zaretsky, J.M.5
Desrichard, A.6
Walsh, L.A.7
Postow, M.A.8
Wong, P.9
Ho, T.S.10
-
35
-
-
84928761118
-
Cancer immunology
-
Rizvi, N. A., M. D. Hellmann, A. Snyder, P. Kvistborg, V. Makarov, J. J. Havel, W. Lee, J. Yuan, P. Wong, T. S. Ho, et al. 2015. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348: 124-128.
-
(2015)
Mutational Landscape Determines Sensitivity to PD-1 Blockade in Non-small Cell Lung Cancer. Science
, vol.348
, pp. 124-128
-
-
Rizvi, N.A.1
Hellmann, M.D.2
Snyder, A.3
Kvistborg, P.4
Makarov, V.5
Havel, J.J.6
Lee, W.7
Yuan, J.8
Wong, P.9
Ho, T.S.10
-
36
-
-
84862859820
-
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer
-
Topalian, S. L., F. S. Hodi, J. R. Brahmer, S. N. Gettinger, D. C. Smith, D. F. McDermott, J. D. Powderly, R. D. Carvajal, J. A. Sosman, M. B. Atkins, et al. 2012. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366: 2443-2454.
-
(2012)
N. Engl. J. Med.
, vol.366
, pp. 2443-2454
-
-
Topalian, S.L.1
Hodi, F.S.2
Brahmer, J.R.3
Gettinger, S.N.4
Smith, D.C.5
McDermott, D.F.6
Powderly, J.D.7
Carvajal, R.D.8
Sosman, J.A.9
Atkins, M.B.10
-
37
-
-
84898973055
-
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab
-
Topalian, S. L., M. Sznol, D. F. McDermott, H. M. Kluger, R. D. Carvajal, W. H. Sharfman, J. R. Brahmer, D. P. Lawrence, M. B. Atkins, J. D. Powderly, et al. 2014. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J. Clin. Oncol. 32: 1020-1030.
-
(2014)
J. Clin. Oncol.
, vol.32
, pp. 1020-1030
-
-
Topalian, S.L.1
Sznol, M.2
McDermott, D.F.3
Kluger, H.M.4
Carvajal, R.D.5
Sharfman, W.H.6
Brahmer, J.R.7
Lawrence, D.P.8
Atkins, M.B.9
Powderly, J.D.10
-
38
-
-
84923078390
-
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
-
Powles, T., J. P. Eder, G. D. Fine, F. S. Braiteh, Y. Loriot, C. Cruz, J. Bellmunt, H. A. Burris, D. P. Petrylak, S. L. Teng, et al. 2014. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515: 558-562.
-
(2014)
Nature
, vol.515
, pp. 558-562
-
-
Powles, T.1
Eder, J.P.2
Fine, G.D.3
Braiteh, F.S.4
Loriot, Y.5
Cruz, C.6
Bellmunt, J.7
Burris, H.A.8
Petrylak, D.P.9
Teng, S.L.10
-
39
-
-
84920956735
-
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
-
Herbst, R. S., J. C. Soria, M. Kowanetz, G. D. Fine, O. Hamid, M. S. Gordon, J. A. Sosman, D. F. McDermott, J. D. Powderly, S. N. Gettinger, et al. 2014. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515: 563-567.
-
(2014)
Nature
, vol.515
, pp. 563-567
-
-
Herbst, R.S.1
Soria, J.C.2
Kowanetz, M.3
Fine, G.D.4
Hamid, O.5
Gordon, M.S.6
Sosman, J.A.7
McDermott, D.F.8
Powderly, J.D.9
Gettinger, S.N.10
-
40
-
-
84929481480
-
Pembrolizumab for the treatment of non-small-cell lung cancer
-
KEYNOTE-001 Investigators
-
Garon, E. B., N. A. Rizvi, R. Hui, N. Leighl, A. S. Balmanoukian, J. P. Eder, A. Patnaik, C. Aggarwal, M. Gubens, L. Horn, et al; KEYNOTE-001 Investigators. 2015. Pembrolizumab for the treatment of non-small-cell lung cancer. N. Engl. J. Med. 372: 2018-2028.
-
(2015)
N. Engl. J. Med.
, vol.372
, pp. 2018-2028
-
-
Garon, E.B.1
Rizvi, N.A.2
Hui, R.3
Leighl, N.4
Balmanoukian, A.S.5
Eder, J.P.6
Patnaik, A.7
Aggarwal, C.8
Gubens, M.9
Horn, L.10
-
41
-
-
84932628341
-
PD-1 blockade in tumors with mismatch-repair deficiency
-
Le, D. T., J. N. Uram, H. Wang, B. R. Bartlett, H. Kemberling, A. D. Eyring, A. D. Skora, B. S. Luber, N. S. Azad, D. Laheru, et al. 2015. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372: 2509-2520.
-
(2015)
N. Engl. J. Med.
, vol.372
, pp. 2509-2520
-
-
Le, D.T.1
Uram, J.N.2
Wang, H.3
Bartlett, B.R.4
Kemberling, H.5
Eyring, A.D.6
Skora, A.D.7
Luber, B.S.8
Azad, N.S.9
Laheru, D.10
-
42
-
-
48249117436
-
High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma: A retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006
-
Klapper, J. A., S. G. Downey, F. O. Smith, J. C. Yang, M. S. Hughes, U. S. Kammula, R. M. Sherry, R. E. Royal, S. M. Steinberg, and S. Rosenberg. 2008. High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma: a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006. Cancer 113: 293-301.
-
(2008)
Cancer
, vol.113
, pp. 293-301
-
-
Klapper, J.A.1
Downey, S.G.2
Smith, F.O.3
Yang, J.C.4
Hughes, M.S.5
Kammula, U.S.6
Sherry, R.M.7
Royal, R.E.8
Steinberg, S.M.9
Rosenberg, S.10
-
43
-
-
37349072460
-
Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis
-
Yang, J. C., M. Hughes, U. Kammula, R. Royal, R. M. Sherry, S. L. Topalian, K. B. Suri, C. Levy, T. Allen, S. Mavroukakis, et al. 2007. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J. Immunother. 30: 825-830.
-
(2007)
J. Immunother.
, vol.30
, pp. 825-830
-
-
Yang, J.C.1
Hughes, M.2
Kammula, U.3
Royal, R.4
Sherry, R.M.5
Topalian, S.L.6
Suri, K.B.7
Levy, C.8
Allen, T.9
Mavroukakis, S.10
-
44
-
-
84929361060
-
Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab
-
McDermott, D. F., C. G. Drake, M. Sznol, T. K. Choueiri, J. D. Powderly, D. C. Smith, J. R. Brahmer, R. D. Carvajal, H. J. Hammers, I. Puzanov, et al. 2015. Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab. J. Clin. Oncol. 33: 2013-2020.
-
(2015)
J. Clin. Oncol.
, vol.33
, pp. 2013-2020
-
-
McDermott, D.F.1
Drake, C.G.2
Sznol, M.3
Choueiri, T.K.4
Powderly, J.D.5
Smith, D.C.6
Brahmer, J.R.7
Carvajal, R.D.8
Hammers, H.J.9
Puzanov, I.10
-
45
-
-
84928195112
-
Cancer immunotherapy
-
Carreno, B. M., V. Magrini, M. Becker-Hapak, S. Kaabinejadian, J. Hundal, A. A. Petti, A. Ly, W. R. Lie, W. H. Hildebrand, E. R. Mardis, and G. P. Linette. 2015. Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science 348: 803-808.
-
(2015)
A Dendritic Cell Vaccine Increases the Breadth and Diversity of Melanoma Neoantigen-specific T Cells. Science
, vol.348
, pp. 803-808
-
-
Carreno, B.M.1
Magrini, V.2
Becker-Hapak, M.3
Kaabinejadian, S.4
Hundal, J.5
Petti, A.A.6
Ly, A.7
Lie, W.R.8
Hildebrand, W.H.9
Mardis, E.R.10
Linette, G.P.11
-
46
-
-
84903846565
-
Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions
-
Lu, Y. C., X. Yao, J. S. Crystal, Y. F. Li, M. El-Gamil, C. Gross, L. Davis, M. E. Dudley, J. C. Yang, Y. Samuels, et al. 2014. Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions. Clin. Cancer Res. 20: 3401-3410. doi:10. 1158/1078-0432. CCR-14-0433.
-
(2014)
Clin. Cancer Res.
, vol.20
, pp. 3401-3410
-
-
Lu, Y.C.1
Yao, X.2
Crystal, J.S.3
Li, Y.F.4
El-Gamil, M.5
Gross, C.6
Davis, L.7
Dudley, M.E.8
Yang, J.C.9
Samuels, Y.10
-
47
-
-
84900301377
-
Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer
-
Tran, E., S. Turcotte, A. Gros, P. F. Robbins, Y. C. Lu, M. E. Dudley, J. R. Wunderlich, R. P. Somerville, K. Hogan, C. S. Hinrichs, et al. 2014. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 344: 641-645.
-
(2014)
Science
, vol.344
, pp. 641-645
-
-
Tran, E.1
Turcotte, S.2
Gros, A.3
Robbins, P.F.4
Lu, Y.C.5
Dudley, M.E.6
Wunderlich, J.R.7
Somerville, R.P.8
Hogan, K.9
Hinrichs, C.S.10
|